Compare Davita Inc (DVA) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Freshworks Inc — how do they compare? Davita Inc trades at $179.75 (market cap $11.72B), while Freshworks Inc trades at $11.97 (market cap $3.31B). The key difference: Davita Inc is far larger — about 3.5× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | FRSH | |
|---|---|---|
Market Cap | $11.72B | $3.31B |
Sector | Health | Technology |
52-Week High | $240.96 | $13.97 |
52-Week Low | $103.87 | $6.88 |
Enterprise Value | $24.44B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Freshworks (FRSH) trades at $11.84, up 2.16% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.17 versus $0.13 expected, and revenue growth of 16% year-over-year. Recent developments include FedRAMP 'In-Process' status for Freshservice and a leadership appointment, reinforcing its competitive position in AI-powered service operations.
The stock offers upside to the $16.50 consensus price target, driven by robust fundamentals like a 20.49% net margin and 19.7% ROE. Risks include high EV/EBITDA valuation and dependence on SaaS sector growth. Analysts are evenly split between Buy and Hold ratings, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
